The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Effects of the Direct Lipoprotein-Associated Phospholipase A 2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque
Open accessAbstract
Background— Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) is expressed abundantly in the necrotic core of coronary lesions, and products of its enzymatic activity may contribute to inflammation and cell death, rendering plaque vulnerable to rupture. Methods and Results— This study compared the effects of 12 months of treatment with darapladib (an oral Lp-PLA 2 inhibitor, 160 mg daily) or placebo on coronary atheroma deformability (intravascular ultrasound palpography) and plasma high-sensitivity C-reactive protein in 330 patients with angiographically documented coronary disease. Secondary end points included changes in necrotic core size (intravascular ultrasound radiofrequency), atheroma size (intravascular ultrasound gray scale), and blood biomarkers. Background therapy was comparable between groups, with no difference in low-density lipoprotein cholesterol at 12 months (placebo, 88±34 mg/dL; darapladib, 84±31 mg/dL; P =0.37). In contrast, Lp-PLA 2 activity was inhibited by 59% with darapladib ( P <0.001 versus placebo). After 12 months, there were no significant differences between groups in plaque deformability ( P =0.22) or plasma high-sensitivity C-reactive protein ( P =0.35). In the placebo-treated group, however, necrotic core volume increased significantly (4.5±17.9 mm 3 ; P =0.009), whereas darapladib halted this increase (−0.5±13.9 mm 3 ; P =0.71), resulting in a significant treatment difference of −5.2 mm 3 ( P =0.012). These intraplaque compositional changes occurred without a significant treatment difference in total atheroma volume ( P =0.95). Conclusions— Despite adherence to a high level of standard-of-care treatment, the necrotic core continued to expand among patients receiving placebo. In contrast, Lp-PLA 2 inhibition with darapladib prevented necrotic core expansion, a key determinant of plaque vulnerability. These findings suggest that Lp-PLA 2 inhibition may represent a novel therapeutic approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Virmani, R., Kolodgie, F. D., Burke, A. P., Farb, A., & Schwartz, S. M. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.5.1262 · Cited by 4,084
Compensatory Enlargement of Human Atherosclerotic Coronary Arteries
Glagov, S., Weisenberg, E., Zarins, C. K., Stankunavicius, R., & Kolettis, G. J. (1987) · New England Journal of Medicine · doi:10.1056/nejm198705283162204 · Cited by 3,623
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Brown, B. G., Ganz, P., Vogel, R. A., Crowe, T., Howard, G., Cooper, C. J., Brodie, B., et al. (2004) · JAMA · doi:10.1001/jama.291.9.1071 · Cited by 2,361
Self-citationNissen, S. E., Nicholls, S. J., Sipahi, I., Libby, P., Raichlen, J. S., Ballantyne, C. M., Davignon, J., Erbel, R., Fruchart, J. C., Tardif, J.-C., et al. (2006) · JAMA · doi:10.1001/jama.295.13.jpc60002 · Cited by 2,047
Angiographic progression of coronary artery disease and the development of myocardial infarction
Ambrose, J. A., Tannenbaum, M. A., Alexopoulos, D., Hjemdahl-Monsen, C. E., Leavy, J., Weiss, M., Borrico, S., Gorlin, R., & Fuster, V. (1988) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(88)90356-7 · Cited by 1,452
Coronary Plaque Classification With Intravascular Ultrasound Radiofrequency Data Analysis
Nair, A., Kuban, B. D., Tuzcu, E. M., Schoenhagen, P., Nissen, S. E., & Vince, D. G. (2002) · Circulation · doi:10.1161/01.cir.0000035654.18341.5e · Cited by 1,129
Self-citationTabas, I. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000184783.04864.9f · Cited by 641
Accuracy of In Vivo Coronary Plaque Morphology Assessment
Nasu, K., Tsuchikane, E., Katoh, O., Vince, D. G., Virmani, R., Surmely, J.-F., Murata, A., Takeda, Y., Ito, T., Ehara, M., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.02.044 · Cited by 496
Self-citationZalewski, A., & Macphee, C. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000160551.21962.a7 · Cited by 474
Self-citation
Cited by
Progress and challenges in translating the biology of atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2011) · Nature · doi:10.1038/nature10146 · Cited by 4,010
Inflammation in Atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.09.009 · Cited by 2,228
Atherosclerosis: current pathogenesis and therapeutic options
Weber, C., & Noels, H. (2011) · Nature Medicine · doi:10.1038/nm.2538 · Cited by 2,203
Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy
Libby, P. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1216063 · Cited by 1,262
Dennis, E. A., Cao, J., Hsu, Y.-H., Magrioti, V., & Kokotos, G. (2011) · Chemical Reviews · doi:10.1021/cr200085w · Cited by 1,203
Phospholipase A2 structure/function, mechanism, and signaling
Burke, J. E., & Dennis, E. A. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800033-jlr200 · Cited by 933
Serruys, P. W., Ormiston, J. A., Onuma, Y., Regar, E., Gonzalo, N., Garcia-Garcia, H. M., Nieman, K., Bruining, N., Dorange, C., Miquel-Hébert, K., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60325-1 · Cited by 820
Self-citationAn Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases
Law, S.-H., Chan, M.-L., Marathe, G. K., Parveen, F., Chen, C.-H., & Ke, L.-Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051149 · Cited by 817
Inflammation in Atherosclerosis: Transition From Theory to Practice
Libby, P., Okamoto, Y., Rocha, V. Z., & Folco, E. (2010) · Circulation Journal · doi:10.1253/circj.cj-09-0706 · Cited by 799
Immune Effector Mechanisms Implicated in Atherosclerosis: From Mice to Humans
Libby, P., Lichtman, A. H., & Hansson, G. K. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.009 · Cited by 671
Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease
The STABILITY Investigators (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315878 · Cited by 579
Anti-inflammatory therapies for cardiovascular disease
Ridker, P. M., & Luscher, T. F. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu203 · Cited by 550
Recent progress in phospholipase A2 research: From cells to animals to humans
Murakami, M., Taketomi, Y., Miki, Y., Sato, H., Hirabayashi, T., & Yamamoto, K. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2010.12.001 · Cited by 507
Adibhatla, R. M., & Hatcher, J. F. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2668 · Cited by 480
Nicholls, S. J., Hsu, A., Wolski, K., Hu, B., Bayturan, O., Lavoie, A., Uno, K., Tuzcu, E. M., & Nissen, S. E. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.026 · Cited by 475
Inflammation and cardiovascular disease: From mechanisms to therapeutics
Alfaddagh, A., Martin, S. S., Leucker, T. M., Michos, E. D., Blaha, M. J., Lowenstein, C. J., Jones, S. R., & Toth, P. P. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100130 · Cited by 473
O’Donoghue, M. L., Braunwald, E., White, H. D., Steen, D. P., Lukas, M. A., Tarka, E., Steg, P. G., Hochman, J. S., Bode, C., Maggioni, A. P., et al. (2014) · JAMA · doi:10.1001/jama.2014.11061 · Cited by 456
Self-citationMolecular Biology of Atherosclerosis
Hopkins, P. N. (2013) · Physiological Reviews · doi:10.1152/physrev.00004.2012 · Cited by 459
The Metabolic Serine Hydrolases and Their Functions in Mammalian Physiology and Disease
Long, J. Z., & Cravatt, B. F. (2011) · Chemical Reviews · doi:10.1021/cr200075y · Cited by 425
Cheng, J. M., Garcia-Garcia, H. M., de Boer, S. P. M., Kardys, I., Heo, J. H., Akkerhuis, K. M., Oemrawsingh, R. M., van Domburg, R. T., Ligthart, J., Witberg, K. T., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht484 · Cited by 379
Self-citationAnti-inflammatory therapies for atherosclerosis
Bäck, M., & Hansson, G. K. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.5 · Cited by 378
Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses
Lenaerts, A., Barry, C. E., & Dartois, V. (2015) · Immunological Reviews · doi:10.1111/imr.12252 · Cited by 362
Kubo, T., Maehara, A., Mintz, G. S., Doi, H., Tsujita, K., Choi, S.-Y., Katoh, O., Nasu, K., Koenig, A., Pieper, M., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.078 · Cited by 351
Self-citationAnti-inflammatory therapeutics for the treatment of atherosclerosis
Charo, I. F., & Taub, R. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3444 · Cited by 306
Serruys, P. W., Garcia-Garcia, H. M., & Onuma, Y. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr384 · Cited by 303
Self-citationDavidson, M. H., Ballantyne, C. M., Jacobson, T. A., Bittner, V. A., Braun, L. T., Brown, A. S., Brown, W. V., Cromwell, W. C., Goldberg, R. B., McKenney, J. M., et al. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.07.005 · Cited by 262
Targeting inflammation to reduce cardiovascular disease risk: A realistic clinical prospect?
Welsh, P., Grassia, G., Botha, S., Sattar, N., & Maffia, P. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13818 · Cited by 164
Grallert, H., Dupuis, J., Bis, J. C., Dehghan, A., Barbalic, M., Baumert, J., Lu, C., Smith, N. L., Uitterlinden, A. G., Roberts, R., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr372 · Cited by 83
Metadata
- Authors
- Serruys, P. W., García-García, H. M., Buszman, P., Erne, P., Verheye, S., Aschermann, M., Duckers, H., Bleie, O., Dudek, D., Bøtker, H. E., von Birgelen, C., D'Amico, D., Hutchinson, T., Zambanini, A., Mastik, F., van Es, G.-A., van der Steen, A. F. W., Vince, D. G., Ganz, P., Hamm, C. W., Wijns, W., & Zalewski, A.
- Venue
- Circulation
- Published
- 2008-09-09
- Volume
- 118
- Issue
- 11
- Pages
- 1172-1182
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2110551379
- Cited by
- 505
- References
- 26
- FWCI
- 62.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.